Potential role of acrolein in neurodegeneration and in Alzheimer's disease

Current Molecular Pharmacology

Volumn 3, Issue 2, 2010, Pages 66-78

  Nam, Dang Thanh ^a   Arseneault, Madeleine ^a   Murthy, Ven ^b   Ramassamy, Charles ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alzheimer's disease; Glutathione; Polyamines; Redox potential; S glutathionylation

Indexed keywords

ACROLEIN; ACTIN; MALONALDEHYDE; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL DEATH; CEREBELLUM; CYTOSKELETON; DNA EXTRACTION; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID PEROXIDATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACROLEIN; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; DNA ADDUCTS; GLUTATHIONE TRANSFERASE; HUMANS; LIPID PEROXIDATION; MICE; POLYAMINES; RATS;

EID: 77953659232     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211003020066     Document Type: Article

References (129)

1. Rhein, V.; Song, X.; Wiesner, A.; Ittner, L.M.; Baysang, G.; Meier, F.; Ozmen, L.; Bluethmann, H.; Drose, S.; Brandt, U.; Savaskan, E.; Czech, C.; Gotz, J.; Eckert, A. myloid- beta and tau synergisti-cally impair the oxidative phosphorylation system in triple trans-genic Alzheimer's disease mice. Proc. Natl. Acad. Sci. USA, 2009, 106, 20057-20062.
2. Aliev, G.; Palacios, H.H.; Walrafen, B.; Lipsitt, A.E.; Obrenovich, M.E.; Morales, L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int. J. Biochem. Cell. Biol., 2009, 41, 1989-2004.
3. Casadesus, G.; Smith, M.A.; Basu, S.; Hua, J.; Capobianco, D.E.; Siedlak, S.L.; Zhu, X.; Perry, G. Increased isoprostane and prosta-glandin are prominent in neurons in Alzheimer disease. Mol. Neu-rodegener, 2007, 2, 2.
4. Reed, T.T.; Pierce, W.M.; Markesbery, W.R.; Butterfield, D.A. Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009, 1274, 66-76.
5. Sultana, N. Proteomics Identification of Carbonylated and HNE- Bound Brain Proteins in Alzheimer's Disease. Methods Mol. Biol., 2009, 566, 123-135.
6. Calingasan, N.Y.; Uchida, K.; Gibson, G.E. Protein-bound ac- rolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem., 1999, 72, 751-756.
7. Sayre, L.M.; Zelasko, D.A.; Harris, P.L.; Perry, G.; Salomon, R.G.; Smith, M.A. 4-Hydroxynonenal-derived advanced lipid peroxida-tion end products are increased in Alzheimer's disease. J. Neuro-chem., 1997, 68, 2092-2097.
8. Montine, K.S.; Olson, S.J.; Amarnath, V.; Whetsell, W.O., Jr.; Graham, D.G.; Montine, T.J. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol., 1997, 150, 437-443.
9. Ramassamy, C.; Averill, D.; Beffert, U.; Bastianetto, S.; Theroux, L.; Lussier-Cacan, S.; Cohn, J.S.; Christen, Y.; Davignon, J.; Quirion, R.; Poirier, J. Oxidative damage and protection by anti-oxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic. Biol. Med., 1999, 27, 544-553.
10. Ramassamy, C.; Averill, D.; Beffert, U.; Theroux, L.; Lussier-Cacan, S.; Cohn, J.S.; Christen, Y.; Schoofs, A.; Davignon, J.; Poirier, J. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol. Dis., 2000, 7, 23-37.
11. Markesbery, W.R.; Lovell, M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging, 1998, 19, 33-36.
12. Montine, K.S.; Reich, E.; Neely, M.D.; Sidell, K.R.; Olson, S.J.; Markesbery, W.R.; Montine, T.J. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J. Neuropathol. Exp. Neurol., 1998, 57, 415-425.
13. Esterbauer, H.; Schaur, R.J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11, 81-128.
14. Marnett, L.J.; Riggins, J.N.; West, J.D. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest., 2003, 111, 583-593.
15. Tillian, H.M.; Schauenstein, E.; Ertl, A.; Esterbauer, H. Therapeutic effects of cysteine adducts of alpha, beta-unsaturated aldehydes on Ehrlich ascites tumor of mice. Eur. J. Cancer, 1976, 12, 989-993.
16. Gan, J.C.; Ansari, G.A. Plausible mechanism of inactivation of plasma alpha 1-proteinase inhibitor by acrolein. Res. Commun. Chem. Pathol. Pharmacol., 1987, 55, 419-422.
17. Kehrer, J.P.; Biswal, S.S. The molecular effects of acrolein. Toxi-col. Sci., 2000, 57, 6-15.
18. Uchida, K.; Kanematsu, M.; Morimitsu, Y.; Osawa, T.; Noguchi, N.; Niki, E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J. Biol. Chem., 1998, 273, 16058-16066.
19. Markesbery, W.R.; Lovell, M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol., 2007, 64, 954-956.
20. Montine, T.J.; Montine, K.S.; McMahan, W.; Markesbery, W.R.; Quinn, J.F.; Morrow, J.D. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid. Redox. Signal, 2005, 7, 269-275.
21. nd; Morrow, J.D.; Montine, T.J. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids, 2004, 128, 117-124.
22. Sonnen, J.A.; Breitner, J.C.; Lovell, M.A.; Markesbery, W.R.; Quinn, J.F.; Montine, T.J. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic. Biol. Med., 2008, 45, 219-230.
23. Montine, T.J.; Neely, M.D.; Quinn, J.F.; Beal, M.F.; Markesbery, W.R.; Roberts, L.J.; Morrow, J.D. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med., 2002, 33, 620-626.
24. Christen, Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr., 2000, 71, 621S-629S.
25. Montine, T.J.; Beal, M.F.; Cudkowicz, M.E.; O'Donnell, H.; Margolin, R.A.; McFarland, L.; Bachrach, A.F.; Zackert, W.E.; Roberts, L.J.; Morrow, J.D. Increased CSF F2-isoprostane concentration in probable AD. Neurology, 1999, 52, 562-565.
26. Lovell, M.A.; Xie, C.; Markesbery, W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging, 2001, 22, 187-194.
27. Williams, T.I.; Lynn, B.C.; Markesbery, W.R.; Lovell, M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging, 2006, 27, 1094-1099.
28. Kawaguchi-Niida, M.; Shibata, N.; Morikawa, S.; Uchida, K.; Yamamoto, T.; Sawada, T.; Kobayashi, M. Crotonaldehyde accumulates in glial cells of Alzheimer's disease brain. Acta Neuropa-thol., 2006, 111, 422-429.
29. Wang, J.Z.; Liu, F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol., 2008, 85, 148-175.
30. Wang, J.Z.; Grundke-Iqbal, I.; Iqbal, K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci., 2007, 25, 59-68.
31. Zhu, X.; Sun, Z.; Lee, H.G.; Siedlak, S.L.; Perry, G.; Smith, M.A. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J. Neurochem., 2003, 86, 136-142.
32. Zhu, X.; Rottkamp, C.A.; Boux, H.; Takeda, A.; Perry, G.; Smith, M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuro-pathol. Exp. Neurol., 2000, 59, 880-888.
33. Schindowski, K.; Bretteville, A.; Leroy, K.; Begard, S.; Brion, J.P.; Hamdane, M.; Buee, L. Alzheimer's disease-like tau neuropathol-ogy leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol., 2006, 169, 599-616.
34. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 759-767.
35. Su, B.; Wang, X.; Lee, H.G.; Tabaton, M.; Perry, G.; Smith, M.A.; Zhu, X. Chronic oxidative stress causes increased tau phosphoryla-tion in M17 neuroblastoma cells. Neurosci. Lett., 2010, 468, 267-271.
36. Diaz-Hernandez, M.; Hernandez, F.; Martin-Aparicio, E.; Gomez-Ramos, P.; Moran, M.A.; Castano, J.G.; Ferrer, I.; Avila, J.; Lucas, J.J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci., 2003, 23, 11653-11661.
37. Kuhla, B.; Haase, C.; Flach, K.; Luth, H.J.; Arendt, T.; Munch, G. Effect of pseudophosphorylation and cross-linking by lipid peroxi-dation and advanced glycation end product precursors on tau aggregation and filament formation. J. Biol. Chem., 2007, 282, 6984-6991.
38. Wolfle, W.T.; Johnson, R.E.; Minko, I.G.; Lloyd, R.S.; Prakash, S.; Prakash, L. Human DNA polymerase iota promotes replication through a ring-closed minor-groove adduct that adopts a syn conformation in DNA. Mol. Cell. Biol., 2005, 25, 8748-8754.
39. Nath, R.G.; Chung, F.L. Detection of exocyclic 1,N2-propanodeoxyguanosine adducts as common DNA lesions in rodents and humans. Proc. Natl. Acad. Sci. USA, 1994, 91, 7491-7495.
40. Nath, R.G.; Ocando, J.E.; Chung, F.L. Detection of 1, N2-propanodeoxyguanosine adducts as potential endogenous DNA lesions in rodent and human tissues. Cancer Res., 1996, 56, 452-456.
41. Chung, F.L.; Young, R.; Hecht, S.S. Formation of cyclic 1,N2-propanodeoxyguanosine adducts in DNA upon reaction with ac-rolein or crotonaldehyde. Cancer Res. 1984, 44, 990-995.
42. Kozekov, I.D.; Nechev, L.V.; Moseley, M.S.; Harris, C.M.; Rizzo, C.J.; Stone, M.P.; Harris, T.M. DNA interchain cross-links formed by acrolein and crotonaldehyde. J. Am. Chem. Soc., 2003, 125, 50-61.
43. Liu, X.; Lovell, M.A.; Lynn, B.C. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal. Chem., 2005, 77, 5982-5989.
44. Liu, X.; Lovell, M.A.; Lynn, B.C. Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. Chem. Res. Toxicol., 2006, 19, 710-718.
45. Kimes, B.W.; Morris, D.R. Preparation and stability of oxidized polyamines. Biochim. Biophys. Acta, 1971, 228, 223-234.
46. Tabor, C.W.; Tabor, H. Polyamines. Annu. Rev. Biochem., 1984, 53, 749-790.
47. Bernstein, H.G.; Muller, M. The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog. Neurobiol., 1999, 57, 485-505.
48. Bernstein, H.G.; Muller, M. Increased immunostaining for L-ornithine decarboxylase occurs in neocortical neurons of Alzheimer's disease patients. Neurosci. Lett., 1995, 186, 123-126.
49. Coffino, P.; Poznanski, A. Killer polyamines? J. Cell. Biochem., 1991, 45, 54-58.
50. Harada, J.; Sugimoto, M. Polyamines prevent apoptotic cell death in cultured cerebellar granule neurons. Brain Res., 1997, 753, 251-259.
51. Yatin, S.M.; Yatin, M.; Varadarajan, S.; Ain, K.B.; Butterfield, D.A. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J. Neurosci. Res., 2001, 63, 395-401.
52. Paschen, W.; Schmidt-Kastner, R.; Djuricic, B.; Meese, C.; Linn, F.; Hossmann, K.A. Polyamine changes in reversible cerebral ischemia. J. Neurochem., 1987, 49, 35-37.
53. Morrison, L.D.; Kish, S.J. Brain polyamine levels are altered in Alzheimer's disease. Neurosci. Lett., 1995, 197, 5-8.
54. Seidl, R.; Beninati, S.; Cairns, N.; Singewald, N.; Risser, D.; Ba-van, H.; Nemethova, M.; Lubec, G. Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. Neurosci. Lett., 1996, 206, 193-195.
55. Adams, J.D., Jr.; Klaidman, L.K. Acrolein-induced oxygen radical formation. Free Radic. Biol. Med., 1993, 15, 187-193.
56. Ramana, K.V.; Dixit, B.L.; Srivastava, S.; Balendiran, G.K.; Sri-vastava, S.K.; Bhatnagar, A. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry, 2000, 39, 12172-12180.
57. Mitchell, D.Y.; Petersen, D.R. Metabolism of the glutathione-acrolein adduct, S-(2-aldehydo-ethyl)glutathione, by rat liver alcohol and aldehyde dehydrogenase. J. Pharmacol. Exp. Ther., 1989, 251, 193-198.
58. Picklo, M.J.; Olson, S.J.; Markesbery, W.R.; Montine, T.J. Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60, 686-695.
59. Wang, X.; Sheikh, S.; Saigal, D.; Robinson, L.; Weiner, H. Hetero-tetramers of human liver mitochondrial (class 2) aldehyde dehy-drogenase expressed in Escherichia coli. A model to study the het-erotetramers expected to be found in Oriental people. J. Biol. Chem., 1996, 271, 31172-31178.
60. Wang, B.; Wang, J.; Zhou, S.; Tan, S.; He, X.; Yang, Z.; Xie, Y.C.; Li, S.; Zheng, C.; Ma, X. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J. Neurol. Sci., 2008, 268, 172-175.
61. Ohta, S.; Ohsawa, I.; Kamino, K.; Ando, F.; Shimokata, H. Mito-chondrial ALDH2 deficiency as an oxidative stress. Ann. N.Y. Acad. Sci., 2004, 1011, 36-44.
62. Kamino, K.; Nagasaka, K.; Imagawa, M.; Yamamoto, H.; Yoneda, H.; Ueki, A.; Kitamura, S.; Namekata, K.; Miki, T.; Ohta, S. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Bio-chem. Biophys. Res. Commun., 2000, 273, 192-196.
63. Ohta, S.; Ohsawa, I. Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J. Alz-heimers Dis., 2006, 9, 155-166.
64. Mitchell, D.Y.; Petersen, D.R. Inhibition of rat liver aldehyde dehydrogenases by acrolein. Drug Metab. Dispos., 1988, 16, 37-42.
65. Lovell, M.A.; Xie, C.; Markesbery, W.R. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic. Biol. Med., 2000, 29, 714-720.
66. Takano, K.; Ogura, M.; Yoneda, Y.; Nakamura, Y. Oxidative metabolites are involved in polyamine-induced microglial cell death. Neuroscience, 2005, 134, 1123-1131.
67. Uchida, K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc. Med., 1999, 9, 109-113.
68. Pocernich, C.B.; Butterfield, D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res., 2003, 5, 515-520.
69. Ansari, M.A.; Keller, J.N.; Scheff, S.W. Protective effect of Pycnogenol in human neuroblastoma SH-SY5Y cells following ac-rolein-induced cytotoxicity. Free Radic. Biol. Med., 2008, 45, 1510-1519.
70. Mello, C.F.; Sultana, R.; Piroddi, M.; Cai, J.; Pierce, W.M.; Klein, J.B.; Butterfield, D.A. Acrolein induces selective protein carbony-lation in synaptosomes. Neuroscience, 2007, 147, 674-679.
71. Jeong, M.S.; Kang, J.H. Acrolein, the toxic endogenous aldehyde, induces neurofilament-L aggregation. BMB Rep., 2008, 41, 635-639.
72. Nakamura, Y.; Hasimoto, R.; Kashiwagi, Y.; Miyamae, Y.; Shino-saki, K.; Nishikawa, T.; Hattori, H.; Kudo, T.; Takeda, M. Abnormal distribution of neurofilament L in neurons with Alzheimer's disease. Neurosci. Lett., 1997, 225, 201-204.
73. Horton, N.D.; Biswal, S.S.; Corrigan, L.L.; Bratta, J.; Kehrer, J.P. Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells. J. Biol. Chem., 1999, 274, 9200-9206.
74. Liu-Snyder, P.; Borgens, R.B.; Shi, R. Hydralazine rescues PC12 cells from acrolein-mediated death. J. Neurosci. Res., 2006, 84, 219-227.
75. Liu, H.; Wang, H.; Shenvi, S.; Hagen, T.M.; Liu, R.M. Glutathione metabolism during aging and in Alzheimer disease. Ann. N.Y. Acad. Sci., 2004, 1019, 346-349.
76. Ansari, M.A.; Scheff, S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neu-rol. 2010, 69, 155-167.
77. Sies, H. Glutathione and its role in cellular functions. Free Radic. Biol. Med., 1999, 27, 916-921.
78. Klatt, P.; Lamas, S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem., 2000, 267, 4928-4944.
79. Newman, S.F.; Sultana, R.; Perluigi, M.; Coccia, R.; Cai, J.; Pierce, W.M.; Klein, J.B.; Turner, D.M.; Butterfield, D.A. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res., 2007, 85, 1506-1514.
80. Wang, Q.; Woltjer, R.L.; Cimino, P.J.; Pan, C.; Montine, K.S.; Zhang, J.; Montine, T.J. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J., 2005,19, 869-871.
81. Sultana, R.; Perluigi, M.; Butterfield, D.A. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 833, 3-11.
82. Lovell, M.A.; Xie, C.; Markesbery, W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology, 1998, 51, 1562-1566.
83. Spalletta, G.; Bernardini, S.; Bellincampi, L.; Federici, G.; Trequat-trini, A.; Ciappi, F.; Bria, P.; Caltagirone, C.; Bossu, P. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am. J. Geriatr. Psychiatry, 2007, 15, 879-887.
84. Pemble, S.; Schroeder, K.R.; Spencer, S.R.; Meyer, D.J.; Hallier, E.; Bolt, H.M.; Ketterer, B.; Taylor, J.B. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J., 1994, 300(Pt1), 271-276.
85. Seidegard, J.; Vorachek, W.R.; Pero, R.W.; Pearson, W.R. Hereditary differences in the expression of the human glutathione trans-ferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA, 1988, 85, 7293-7297.
86. Rebbeck, T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev., 1997, 6, 733-743.
87. Berhane, K.; Widersten, M.; Engstrom, A.; Kozarich, J.W.; Man-nervik B. Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxi-dation by human glutathione transferases. Proc. Natl. Acad. Sci. USA, 1994, 91, 1480-1484.
88. Zhang, H.; Forman, H.J. Signaling pathways involved in phase II gene induction by {alpha}, {beta}-unsaturated aldehydes. Toxicol. Ind. Health, 2009, 25, 269-278.
89. Schipper, H.M. Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med., 2004, 37, 1995-2011.
90. Zhong, L.; Holmgren, A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem., 2000, 275, 18121-18128.
91. Lee, S.R.; Bar-Noy, S.; Kwon, J.; Levine, R.L.; Stadtman, T.C.; Rhee, S.G. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc. Natl. Acad. Sci. USA, 2000, 97, 2521-2526.
92. Bjornstedt, M.; Hamberg, M.; Kumar, S.; Xue, J.; Holmgren, A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J. Biol. Chem.,1995, 270, 11761-11764.
93. Das, K.C.; Lewis-Molock, Y.; White, C.W. Elevation of manganese superoxide dismutase gene expression by thioredoxin. Am. J. Respir. Cell. Mol. Biol., 1997, 17, 713-726.
94. Nikitovic, D.; Holmgren, A. S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J. Biol. Chem., 1996, 271, 19180-19185.
95. Sun, Q.A.; Wu, Y.; Zappacosta, F.; Jeang, K.T.; Lee, B.J.; Hatfield, D.L.; Gladyshev, V.N. Redox regulation of cell signaling by sele-nocysteine in mammalian thioredoxin reductases. J. Biol. Chem., 1999, 274, 24522-24530.
96. Park, Y.S.; Misonou, Y.; Fujiwara, N.; Takahashi, M.; Miyamoto, Y.; Koh, Y.H.; Suzuki, K.; Taniguchi, N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 2005, 327, 1058-1065.
97. Yang, X.; Wu, X.; Choi, Y.E.; Kern, J.C.; Kehrer, J.P. Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology, 2004, 204, 209-218.
98. Akterin, S.; Cowburn, R.F.; Miranda-Vizuete, A.; Jimenez, A.; Bogdanovic, N.; Winblad, B.; Cedazo-Minguez, A. Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell. Death Differ., 2006, 13, 1454-1465.
99. Kruman, I.; Bruce-Keller, A.J.; Bredesen, D.; Waeg, G.; Mattson, M.P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci., 1997, 17, 5089-5100.
100. Pugazhenthi, S.; Phansalkar, K.; Audesirk, G.; West, A.; Cabell, L. Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic. Biol. Med., 2006, 40, 21-34.
101. Tanel, A.; Averill-Bates, D.A. P38 and ERK mitogen-activated protein kinases mediate acrolein-induced apoptosis in Chinese hamster ovary cells. Cell. Signal, 2007, 19, 968-977.
102. Cenini, G.; Sultana, R.; Memo, M.; Butterfield, D.A. Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. J. Cell. Mol. Med., 2008, 12, 987-994.
103. Cenini, G.; Sultana, R.; Memo, M.; Butterfield, D.A. Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic. Biol. Med., 2008, 45, 81-85.
104. Liu-Snyder, P.; McNally, H.; Shi, R.; Borgens, R.B. Acrolein-mediated mechanisms of neuronal death. J. Neurosci. Res., 2006, 84, 209-218.
105. Mirkovic, N.; Voehringer, D.W.; Story, M.D.; McConkey, D.J.; McDonnell, T.J.; Meyn, R.E. Resistance to radiation-induced apop- tosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene, 1997, 15, 1461-1470.
106. Bader Lange, M.L.; Cenini, G.; Piroddi, M.; Abdul, H.M.; Sultana, R.; Galli, F.; Memo, M.; Butterfield, D.A. Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease. Neurobiol. Dis., 2008, 29, 456-464.
107. Castegna, A.; Lauderback, C.M.; Mohmmad-Abdul, H.; Butter-field, D.A. Modulation of phospholipid asymmetry in synaptoso-mal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res., 2004, 1004, 193-197.
108. Daleke, D.L. Regulation of transbilayer plasma membrane phos-pholipid asymmetry. J. Lipid Res., 2003, 44, 233-242.
109. Daleke, D.L.; Lyles, J.V. Identification and purification of amino-phospholipid flippases. Biochim. Biophys. Acta, 2000, 1486, 108-127.
110. Bader Lange, M.L.; St Clair, D.; Markesbery, W.R.; Studzinski, C.M.; Murphy, M.P.; Butterfield, D.A. Age-related loss of phos-pholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: Relevance to Alzheimer disease. Neurobiol. Dis., 2010, 38, 104-15.
111. Su, B.; Wang, X.; Bonda, D.; Perry, G.; Smith, M.; Zhu, X. Abnormal Mitochondrial Dynamics-A Novel Therapeutic Target for Alzheimer's Disease? Mol. Neurobiol., 2010 Jan 27. [Epub ahead of print]
112. Reddy, P.H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp. Neurol., 2009, 218, 286-292.
113. Sultana, R.; Butterfield, D.A. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr., 2009, 41, 441-446.
114. Luo, J.; Robinson, J.P.; Shi, R. Acrolein-induced cell death in PC12 cells: role of mitochondria-mediated oxidative stress. Neuro-chem. Int., 2005, 47, 449-457.
115. Sultana, R.; Poon, H.F.; Cai, J.; Pierce, W.M.; Merchant, M.; Klein, J.B.; Markesbery, W.R.; Butterfield, D.A. Identification of nitrated proteins in Alzheimer's disease brain using a redox pro-teomics approach. Neurobiol. Dis., 2006, 22, 76-87.
116. Furuhata, A.; Nakamura, M.; Osawa, T.; Uchida, K. Thiolation of protein-bound carcinogenic aldehyde. An electrophilic acrolein-lysine adduct that covalently binds to thiols. J. Biol. Chem., 2002, 277, 27919-27926.
117. Tanel, A.; Averill-Bates, D.A. The aldehyde acrolein induces apop-tosis via activation of the mitochondrial pathway. Biochim. Bio-phys. Acta, 2005, 1743, 255-267.
118. Tanel, A.; Averill-Bates, D.A. Inhibition of acrolein-induced apop-tosis by the antioxidant N-acetylcysteine. J. Pharmacol. Exp. Ther., 2007, 321, 73-83.
119. Li, L.; Hamilton, R.F.J.; Taylor, D.E.; Holian, A. Acrolein-induced cell death in human alveolar macrophages. Toxicol. Appl. Pharmacol., 1997, 145, 331-339.
120. Nardini, M.; Finkelstein, E.I.; Reddy, S.; Valacchi, G.; Traber, M.; Cross, C.E.; van der Vliet, A. Acrolein-induced cytotoxicity in cultured human bronchial epithelial cells. Modulation by alpha-tocopherol and ascorbic acid. Toxicology, 2002, 170, 173-185.
121. Takeuchi, K.; Kato, M.; Suzuki, H.; Akhand, A.A.; Wu, J.; Hos-sain, K.; Miyata, T.; Matsumoto, Y.; Nimura, Y.; Nakashima, I. Acrolein induces activation of the epidermal growth factor receptor of human keratinocytes for cell death. J. Cell. Biochem., 2001, 81, 679-688.
122. Ranganna, K.; Yousefipour, Z.; Nasif, R.; Yatsu, F.M.; Milton, S.G.; Hayes, B.E. Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells. Mol. Cell. Biochem., 2002, 240, 83-98.
123. Nana-Sinkam, S.P.; Lee, J.D.; Sotto-Santiago, S.; Stearman, R.S.; Keith, R.L.; Choudhury, Q.; Cool, C.; Parr, J.; Moore, M.D.; Bull, T.M.; Voelkel, N.F.; Geraci, M.W. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am. J. Respir. Crit. Care Med., 2007, 175, 676-685.
124. Desmeules, P.; Devine, P.J. Characterizing the ovotoxicity of cy-clophosphamide metabolites on cultured mouse ovaries. Toxicol. Sci., 2006, 90, 500-509.
125. Shamoto-Nagai, M.; Maruyama, W.; Kato, Y.; Isobe, K.; Tanaka, M.; Naoi, M.; Osawa, T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neu-rosci. Res., 2003, 74, 589-597.
126. Misonou, Y.; Takahashi, M.; Park, Y.S.; Asahi, M.; Miyamoto, Y.; Sakiyama, H.; Cheng, X.; Taniguchi, N. Acrolein induces Hsp72 via both PKCdelta/JNK and calcium signaling pathways in human umbilical vein endothelial cells. Free Radic. Res. 2005, 39, 507-512.
127. Schwerdt, G.; Gordjani, N.; Benesic, A.; Freudinger, R.; Wollny, B.; Kirchhoff, A.; Gekle, M. Chloroacetaldehyde- and acrolein- induced death of human proximal tubule cells. Pediatr. Nephrol., 2006, 21, 60-67.
128. Finkelstein, E.I.; Ruben, J.; Koot, C.W.; Hristova, M.; van der Vliet, A. Regulation of constitutive neutrophil apoptosis by the alpha,beta-unsaturated aldehydes acrolein and 4-hydroxynonenal. Am. J. Physiol. Lung Cell. Mol. Physiol., 2005, 289, L1019-1028.
129. Lambert, C.; Li, J.; Jonscher, K.; Yang, T.C.; Reigan, P.; Quintana, M.; Harvey, J.; Freed, B.M. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J. Biol. Chem., 2007, 282, 19666-19675.